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Abstract
Background: Cholera, an ancient scourge, continues to inflict high rates of mortality today. The rising incidence of
epidemics in areas of poor sanitation and crowding highlight the need for better epidemic prevention and early response.
Such interventions require the availability of rapid and accurate diagnostic techniques to trigger timely response and
mitigate the scale of the outbreak. The current gold standard of bacterial culture is inadequate for rapid diagnosis,
highlighting the overarching neglect of field diagnostic needs. This paper was written to support the World Health
Organisation’s Global Task Force on Cholera Control mandated Cholera and diarrhoeal disease laboratory Network
(CholdiNet) in devising a protocol for the validation of Rapid Diagnostic Tests (RDTs) for Vibrio cholerae. The status of
diagnostic tools for Vibrio cholerae is assessed, describing products that have been commercialised over the last two
decades and discussing their peer-reviewed evaluation.
Method: Review of post-1990 peer-reviewed and grey literature on rapid diagnostic tests for Vibrio cholerae.
Results: Since 1990, twenty four diagnostic tests have been developed for the detection of Vibrio cholerae in human faecal
samples. Fourteen of these have also been described in the literature, with rapid chromatographic-immuno assays (CIA)
featuring strongly. Polymerase chain reaction (PCR) assays maintain the ability to detect the lowest amount of bacteria;
however CIAs achieve both low detection thresholds and high sensitivity and specificity, making them possible candidates
for use in field conditions. Field and laboratory studies were performed in a wide range of settings demonstrating variability
in performance, however only a few of these studies were sufficiently stringent, highlighting five RDTs that showed promise
in field conditions; COAT, IP cholera dipstick, SMART, IP dipstick and Medicos. In light of non-independent reporting, the
authors would like to see these five products undergoing additional studies, with further technical improvements if needed
and commercial production. The authors hope that public health use of such a RDT in limited-resource field conditions on
stool samples may contribute to effective reduction in cholera epidemic spread.
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Introduction
Cholera is an infectious disease caused by the bacteria Vibrio
cholerae O1 and/or O139. When ingested, its clinical sequelae
include the acute onset of severe secretory ‘rice water’ diarrhoea.
Within three to four hours of symptom onset, a previously healthy
individual may become severely dehydrated and if not treated may
die within twenty four hours. This makes cholera one of the most
rapidly fatal infectious illnesses known whose clinical management,
simple rehydration, can be instituted empirically and remains
cheap, safe and life-saving [1].
Cholera inflicts a heavy economic burden in its endemic settings
due to its rapid spread and ability to cause large epidemics [2–3].
Since the first reported epidemic in the 19th century on the Indian
subcontinent, cholera has spread to all inhabited continents and has
become endemic in Africa, South and East Asia [4–5]. In recent
years, reported cholera cases increased steadily reaching more than
300’ 000 cases including more than 7’500 deaths during 2010 [6].
During the same year and for the first time since 1995, the proportion
of global cases reported toWHO from the African continent declined
from more than 90% to less than 50%, a consequence of the large
cholera outbreak which occurred in Hispaniola.
Recent trends suggest that the number of outbreaks of cholera
will continue to increase in vulnerable areas in the future. As
populations of poor countries continue to coalesce in mega-cities
with poor sanitation and people move rapidly around the globe,
new and more virulent strains of V. cholerae are expected to
disseminate more rapidly [7–8]. The unpredictable emergence
and spread of antibiotic-resistant strains, together with increasing
severe weather events and changes in water temperature and
nutrient levels means that the occurrence of more frequent cholera
outbreaks may continue to occur in the foreseeable future [9].
To combat this threat, attention in clinical and public health
circles has expanded to encompass efforts to improve sanitation
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and utilization of new vaccines to improving epidemic response
through early detection. By detecting cholera outbreaks as early in
their course as possible additional resources can be more rapidly
brought to bear to mitigate the size, scope and duration of the
outbreak and subsequent spread of the illness. In addition, using a
cheap rapid diagnostic test on watery stool samples, under field
conditions with limited resources holds great potential to aid
cholera control efforts, not because empirical treatment or later
treatment is less effective but rather because decreasing the
numbers of cholera infections and aiding in epidemic-preventing
surveillance will free up resources that should be directed towards
the excessively complex task of fixing the underlying socio-
economic and environmental factors that propagate the spread of
cholera. This shifts the focus from response measures, which often
arrive too late to halt the course of an epidemic.
With this approach in mind, the current gold standard for
laboratory diagnosis of cholera becomes evidently inadequate due
to lengthy culturing on selective growth media. Preliminary
identification based on colony appearance on Thiosulfate Citrate
Bile Salts Sucrose Agar (TCBS) is traditionally confirmed using an
array of biochemical tests, taking a few days to confirm a case of
cholera and requiring numerous laboratory resources [10]. Such
tests still have a role in antibiotic sensitivity surveillance during
epidemics, however timely field diagnosis calls for Rapid
Diagnostic Tests (RDTs). Most RDTs work by capturing a
characteristic component of the cholera bacteria on a solid surface
and binding it with specific reagents to produce a visual change,
allowing for rapid detection of a cholera infection. Following the
principle of commercialised home-pregnancy detection kits, such
cassettes and dipsticks (characterised by quick turnover time, ease
of use and accuracy) are extending their reach outside classical
laboratory networks thereby aiding diagnosis in under resourced
field settings. The last twenty years have also seen attempts to
modify technologies such as Polymerase Chain Reaction (PCR),
Enzyme Linked Immunosorbent Assay (ELISA) and agglutination
methods to make them more applicable as triggers for the timely
response against cholera.
At the time of writing there is no consensus as to the most
efficacious cholera diagnostic for early case detection. Very few
diagnostic tests have been well described and throroughly
evaluated [11]. This study aims to identify and describe all the
commercialised diagnostic tools developed and evaluated since
1990. It then explores the evidence base for these tests, including
their sensitivity, specificity and reliability. In doing so the paper
exposes the discrepancies that exist between research and field
application of these diagnostic products. The authors hope that
this work will facilitate future consensus regarding the best
diagnostic for early cholera epidemic detection, and hence begin
to address the neglect of cholera.
Methods
Systematic searches were conducted using PubMed, SCOPUS,
EMBASE, LILACS, ScienceDirect, GoogleScholar, Medline Plus,
and ResearchGATE. The following search strategy was used: All
published English literature since 1990 focusing on diagnostic tools
for human clinical samples of cholera, and the evaluation of
diagnostic tests, using the initial terms ‘‘Cholera’’[Mesh] OR
‘‘Vibrio cholerae’’[Mesh] OR cholerae OR Choleras OR cholera
OR ‘‘Cholera Toxin’’[Mesh] AND ‘‘Sensitivity and Specificity’’[-
Mesh] OR ‘‘Diagnosis’’[Mesh] OR ‘‘diagnosis’’[Subheading] OR
(routine AND (test OR tests or testing)) [TIAB] OR (false AND
((positive or positivity) or negative)) [TIAB] OR diagnos* [TIAB]
in PubMed. The reference lists of relevant papers were followed
and a manual search was conducted of journal titles with multiple
publications on the topic, including; Journal of Clinical Microbi-
ology, Transactions of the Royal Society of Tropical Medicine and
Hygiene, Biosensors and Bioelectronics, Journal of Microbiolog-
ical Methods. To elicit information regarding commercialised
diagnostic tools, a grey literature search was conducted of
manufacturers and governmental regulatory websites, following
up manufacturing and product names referred to in the
aforementioned literature. The choice to limit the articles to the
year 1990 reflects the upsurge of technologies following the South
American outbreak of the early 1990s and the discovery of the new
strain O139 Bengal in 1992. Furthermore, papers were excluded if
they did not focus on diagnosis of human samples of Vibrio cholerae
(Figure 1).
At the analysis stage, the diagnostic technologies were described
in terms of: their detection limit, their diagnostic target, the
method used (microscopy, agglutination, ELISA, immunochro-
matography or PCR), turn around time, intended use and settings
of use. The sensitivity and specificity of the tests were reported
from laboratory evaluation, highlighting field studies (when
performed). These field studies were then filtered for having a
sample size greater than 100 stool samples and reporting Positive
Predictive Value (PPV) and Negative Predictive Value (NPV) and
presented in tabulated form according to the aformentioned
values. Following this, a review of the evidence on the validity and
reproducibility underpinning the rapid diagnostic tests (RDTs) was
performed.
Results
Diagnostic Tests
In January 2010, twenty four commercialised diagnostic tests
were identified (Table S1). Ten more received a mention in the
literature but due to suspected discontinuation of production or
fall-back did not provide sufficient information (see note under
table S1 for details). Of the twenty four described in detail below,
a clear evolution is portrayed following closely the historical
Author Summary
Rising prevalence of cholera outbreaks highlights the need
for accurate detection tools. Diagnosing cholera early at
the onset of an epidemic, at field level, should allow for a
more timely response and a quick containment of the
spread and thus a diminished case load. Currently the gold
standard to identify the bacteria, Vibrio cholerae, from
patient samples remains reliant on lengthy bacterial
cultures and an array of biochemical tests. Furthermore,
the need for highly-skilled operators and numerous
laboratory resources underline the inadequacy of sophis-
ticated tests for use in remote locations. Research to
develop more appropriate tools has largely focused on
rapid diagnostic tests and attempts to simplify existing
technologies. This is yet to deliver evidence-based appro-
priate tools to address the burden-of-disease cholera
inflicts. In light of this neglect we have taken the first
step, assessing developments in commercialised diagnos-
tic tools, reviewing previous evaluations undertaken in the
literature since 1990. In doing so, we highlight evaluation
study parameters that could benefit from stringent
standardisation, and identify five tests that show promise
for use in field conditions. The authors recommend an
indipendent assessment of these products, including
technical improvements as required and production to
trigger early detection of cholera epidemics.
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development of diagnostic technologies in this field from cell
culture and microscopy methods towards agglutination methods,
immunochromatographic assays, and Polymerase Chain Reaction
(PCR)-based assays. The majority of tests were found to be based
on antigen or antibody detection, with a large proportion of the
remaining tests being DNA-based. It is important to note that this
investigation came across many diagnostic methods that have
never been commercialised including those that are currently in
the scientific pipeline – technologies such as microarrays and
electro-chemiluminescence are being developed as biosensors for
cholera toxin and other antigens. Loop-mediated isothermal
amplification (LAMP), ELISA and simplified PCR protocols are
but a few of the new approaches to the diagnosis of cholera that
are likely to be seen in the future, unfortunately these are beyond
the scope of this paper.
Table S1 summarises the results in two sections, separating
DNA from antigen detection. All of the tools are described
according to the information provided by the manufacturer;
product parameters, intended application and performance. The
details provided should allow the reader to compare both the
analytical sensitivity, according to the limit of detection, and test
utility according to the turnaround time.
Diagnostic Evaluations of rapid tests
Since 1990 there have been eighteen laboratory and field
evaluations of commercial diagnostic tools for the detection of
Vibrio cholerae in clinical samples (see Tables S2 & S3) [12–29].
These evaluations have been carried out around the world, with a
large proportion taking place in the Indian subcontinent. The
largest study enrolled around 400 cases and controls, while most
other sample cohorts were quite small, the smallest being just 30
patient samples [30]. Tables S2 and S3 summarise the peer
reviewed evaluations of the aforementioned diagnostic tests
conducted between 1990 and 2008. Table S2 highlights those
tests conducted in field conditions. Fourteen different diagnostic
tests were found to have been evaluated and are thus compared
here. Tables 1 and 2 rank those tests that were evaluated under
field conditions with over 100 samples, excluding tests where
negative and positive predictive values were insufficiently reported.
Overall, there appear to be five such tests; coagglutination test
Figure 1. Process of article selection for diagnostic evaluation.
doi:10.1371/journal.pntd.0001845.g001
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(COAT), Institute Pasteur (IP) cholera dipstick, Sensitive Mem-
brane Antigen Rapid Test (SMART), IP dipstick and Medicos.
Tables 3 and 4 similarily present the sensitivities and specificities of
the aformentioned eighteen evaluations by rank of test.
Discussion
Alongside other diarrheal diseases, cholera is a major cause of
preventable childhood and adult deaths in developing countries
[31–32]. Given international attempts like the fourth millennium
development goal (MDG) to reduce such burdens, it is surprising
that cholera has not gained more public health attention.
Availability of rapid diagnostic tests would be extremely useful
for diagnosing cholera epidemics early during their onset in the
field, using watery stool samples from patients at the bed side. Yet
out of 15.7 million US dollars spent by US government in 2007 on
cholera research, only 1% went to diagnostic testing. The scale of
scientific spending on the development and implementation of
diagnostic and therapeutic intervention for cholera is dispropor-
tional to the impact of the disease [33], moving the authors to
conclude that cholera is a ‘neglected disease’. [34].
On the background of such neglect, the authors found twenty
four commercialised diagnostic tools for the detection of Vibrio
cholerae in patient samples. The majority of these tests were of the
rapid detection kind, utilising immunochromatography, direct
fluorescence or agglutination to identify Vibrio cholerae antigens in
stool samples. Due to the reality of limited resource availability, it
would be logical to choose the best tests from those already
available, based on pre-existing evaluations. At the time of
writing, the authors could not find any literature reviews of
diagnostic tools comparable to the scale of this study. At best,
papers describe the comparison in efficacy between three
diagnostic tools [14]. Those aforementioned diagnostic evalua-
tions appear to have a number of limitations. An overarching
problem is the lack of standardisation of assessment criteria,
making comparison between different diagnostic tests very
difficult. This issue has been addressed previously in the
Diagnostic Evaluation Expert Panel (DEEP) guidelines which
provide guidance towards an improved assessment of the
performances of many diagnostic tests in the case of malaria,
dengue, visceral leishmaniasis and tuberculosis. [35]. A number
of critical parameters should be carefully assessed when designing
a diagnostic test evaluation (summarised in table 5).
One implication of this critique of present evaluations is that
even though it would appear at first that a particular test has
the best PPV, NPV, specificity or sensitivity, the limitations of the
evaluations means that no one diagnostic can be recommended
without further improvement and standardized evaluation.
Intended use
It is important to note that the scientific community remains
divided regarding the intended use of rapid cholera tests, failing to
provide any clear consensus about the requirements for such a
rapid diagnostic test. In trying to formulate such requirements one
must recognise the stark difference between individual diagnostic
utility and early detection of epidemic or other public health roles.
This preliminary step is critical as the characteristics of the tests
are expected to differ in each scenario. In the case of PCR
technologies, they currently have an important role in individual
diagnostic confirmation but also play a role in outbreak detection
in combination with RDTs through epidemiology and surveil-
lance. PCR methods have shown to be advantageous at being
particularly sensitive to small amounts of infectious bacteria and
having the added value of characterising the strains of the
epidemic during the same diagnostic investigation. The tests in
Table 1. Positive Predictive Value ranking.
Rank Product name PPV
1[18] (Arya) COAT 100
2[15] (Nato) IP cholera dipstick 95.6
3[15] (Nato) IP cholera dipstick 94.8
4[15] (Nato) IP cholera dipstick 86
5[14] (Kalluri) SMART 84
6[14] (Kalluri) IP dipstick 83
7[14] (Kalluri) Medicos 71
doi:10.1371/journal.pntd.0001845.t001
Table 2. Negative Predictive Value ranking.
Rank Product name NPV
1[15] (Nato) IP cholera dipstick 100
2[15] (Nato) IP cholera dipstick 98.6
3[18] (Arya) COAT 95
4[15] (Nato) IP cholera dipstick 93.3
5[14] (Kalluri) Medicos 90
6[14] (kalluri) IP dipstick 88
7[14] (kalluri) SMART 84
Tables 1 and 2 highlight those tests that were evaluated under field conditions
with over 100 samples, excluding tests where this information was insufficiently
reported.DFA = Direct Fluorescent Antibody, IP = Institute Pasteur, COAT =
Coagglutination Test, VC = Vibrio cholerae, SMART = Sensitive Membrane
Antigen Rapid Test.
doi:10.1371/journal.pntd.0001845.t002
Table 3. Specificity ranking.
Rank Product name Value
1[21] Colwell Cholera Screen 100
2[20] Hasan Cholera SMART 100
3[16] Hasan Bengal Screen 100
4[17] Islam Cholera SMART 100
5[19] Hasan DFA COLTA 100
6[18] Arya COAT 100
7[20] Hasan Cholera SMART 100
8[15] Nato IP cholera dipstick 96
9[14] Kalluri SMART 95
10[15] Nato IP cholera dipstick 92.5
11[16] Hassan Bengal DFA 89
12[13] Wang IP O1 cholera dipstick 89
13[15] Nato IP cholera dipstick 84
14[14] Kalluri Medicos 79
15[21] Colwell Cholera Screen 77.8
16[12] Harris Crystal VC 71–76
17[14] Kalluri IP dipstick 67
18[21] Colwell Cholera Screen 60
doi:10.1371/journal.pntd.0001845.t003
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table S1 detect a range of genes including those that differentiate
between biotype El tor and classical cholera, the serotype specific
wbe and hemA genes and virulence genes for cholera toxin (ctx),
zonula occludens toxin (zot), accessory cholera enterotoxin (ace)
and a tetracycline resistant genotype (tetA). Such tests could be of
great utility if they continue in their adaptation for field use,
especially in surveillance programs within the reach of reference
laboratories. Their limited value in field settings highlights that a
single test cannot serve all contexts and that the end user should be
clearly informed about the limitations of each technology.
Study design
As stipulated in the DEEP guidelines, the study design is the first
parameter to consider to ensure that an evaluation study will
answer the intended question, be it a lab evaluation or field testing.
NPV and PPV can only be derived from field testing when disease
prevalence is known. It is therefore critical that studies analysing
cholera diagnostic tests mimic the conditions the tests are designed
to be used in. Among the rapid diagnostic test evaluations, only a
limited number of studies were conducted in field conditions on
fresh stool samples with provision of population descriptors. Such
demographics may ensure that tests are really applicable to those
who suffer from cholera. Therefore it is not unreasonable to
suggest that current tests may encounter unexpected results when
taken to the field. In the studies analyzed, recurrent conflation of
the term ‘sensitivity’ to describe the lowest detectable dilution in
the stools made it more difficult to carry out an accurate
comparison of the tests. However, overall, some of the new rapid
tests (Smart Q – 105 CFU/mL) are performing to the same
detection standards as the PCR based tests (BAX - 104 CFU/mL).
Table 4. Sensitivity ranking.
Rank Product name Value
1[15] Nato IP cholera dipstick 100
2[16] Hassan Bengal DFA 100
3[21] Colwell Cholera Screen 100
4[20] Hasan Cholera SMART 100
5[19] Hasan DFA COLTA 100
6[17] Islam Cholera SMART 100
7[15] Nato IP cholera dipstick 98.5
8[21] Colwell Cholera Screen 98
9[12] Harris Crystal VC 97
10[20] Hasan Cholera SMART 95.6
11[13] Wang IP O1 cholera dipstick 95
12[16] Hasan Bengal Screen 95
13[15] Nato IP cholera dipstick 94.2
14[18] Arya COAT 92
15[21] Colwell Cholera Screen 85.7
16[14] Kalluri Medicos 84
17[14] Kalluri IP dipstick 83
18[14] Kalluri SMART 58
Tables 3 and 4 list cholera diagnostic tests’ specificity and sensitivity values as
reported by field and laboratory evaluations. SMART= Sensitive Membrane
Antigen Rapid Test, DFA =Direct Fluorescent Antibody, IP = Institute Pasteur,
COAT=Coagglutination Test, VC =Vibrio cholerae.
doi:10.1371/journal.pntd.0001845.t004
Table 5. Recommendations made to address shortcomings of diagnostic test evaluations.
PROBLEMS PROPOSED SOLUTIONS
STUDY DESIGN
1 Small sample size
N Limits validity and reproducibility
Larger studies are feasible
2 Variable sample type
N Fresh vs. archives
Controversial
3 Gold standard
N Uncertain standard case definition
N Newer tests outperforming old
Recommend reviewing gold standard according to
accuracy, cognisant of different uses for different contexts
4 Testing stools vs. purified cultures
N Affects specificity
Stool samples should be used
5 Not approximating field conditions
N Population descriptors are essential for PPV, NPV
Population descriptors should be reported for every
population studied
6 Specificity
N Limited data against common gut organisms
Specificity testing against confounding gut microflora
should be considered prior to commercialisation
TEST DESCRIPTORS
7 Little data available on stability
N Importance of climate variations i.e. temperature, humidity on shelf life and accuracy
Manufacturers should perform stability studies (real time
preferably)
8 Reporting of reproducibility
N Between different users
N As an inherent quality of the tools
N Assessment of manufacturing and inter-lot variation
User reproducibility reported between at least three users
and with sufficient number of samples
SCIENTIFIC RIGOR
9 Conflation sensitivity with lowest detectable dilution Scientific rigor should be a criteria for further inclusion and
re-evaluation of test
doi:10.1371/journal.pntd.0001845.t005
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Sample size and target population
A key study design parameter is the sample size of the
investigation. A small sample size limits the validity of the evaluation
and the reproducibility of the results. This was the case in most of
the evaluations examined, suggesting a direct impact on their
specificity and sensitivity measurements. Indeed many of the studies
were found to have 100% sensitivity or specificity using approxi-
mately 100 participants. In spite of this caveat, it is important to
recognize that due to the challenge of long-term preservation of
cholera organisms in stools specimen sample archives are hard to
come by and conducting the study on larger sample size of fresh
faecal samples in a resource-poor setting is challenging. However, in
the broader literature covered during the course of this analysis, four
larger cohorts were found, each reviewing tests that have not yet to
our knowledge become commercialised (hence being excluded from
the final analysis) [36–38]. The largest investigation by far was a
collection of 6,497 hospital patients by Chaicumpa et al in 1998 [39]
suggesting that such numbers are not impossible and that current
sub-standard sample sizes should not be allowed to become the
acceptable norm.
Another point to consider is whether sample archives are ideal for
a disease like cholera, and whether greater benefit may be gained
from the acquisition and analysis of fresh samples. For example, if
fecal material from children was under-represented in the study
population, health workers may find that the tests are not as accurate
or more prone to diagnostic errors. Such errors relate to our ability to
infer test efficacy from the field data. Since positive predictive values
and negative predictive values are dependent on the prevalence of
the disease in the population, a factor that can differ between
different age groups, the utility of these tests may differ for children.
As children tend to experience greater mortality in association with
severe cholera, it is paramount to diagnose the onset rapidly.
Choice of gold standard
Studies lacked a consistent comparison to any one gold
standard, many studies neglecting to undertake detection by both
test and reference methods across the sample range to confirm the
validity of the result. The variability in the use of sample panels
and study populations underlined the lack of a standardised case
definition. The absence of a clear benchmark for assessing the tests
is made worse by the newer tests performing better than the gold
standard, leaving no adequate comparator. Furthermore, some of
the diagnostic tests were tested against purified cultures of cholera.
This fails to assess how they would fare when used with real
patient stool samples packed with gut micro flora and likely to
have many other contaminating interactions. Therefore, if used,
the results of this investigation are only valid for the use of the
diagnostic after culturing, hence defeating the purpose of making
these into rapid diagnostic tests.
Test panel composition and challenge panels
Following the same principle, many of the tests appear to be
rather specific on first glance, however only few were thoroughly
tested against confounding microorganisms commonly found in
stool samples which could lead to a similar case presentation of
watery stools. Some studies went so far as to not utilise a negative
control. Testing performance against a well characterised chal-
lenge panels is required.
Robustness of the product: reproducibility and heat
stability
Data showing robustness of the test design are important to
support deployment in the areas of highest need. Test descriptors
such as a test’s reproducibility were markedly underreported;
lacking rigorous replication important for assessing the inherent
quality of the diagnostic tool, the reliability of different production
lots and the ease of replication by different users. This also
reflected the lack of important mention of test heat stability. A
test’s intended use is directly linked to analytical parameters such
as heat stability. In the case of cholera much of its endemic settings
are affected by harsh temperatures and humidity, factors which
must be taken into account for the shelf life and accuracy of the
test.
It is important to note that this is not a true systematic analysis,
nor did the analysis review the entire literature, the authors
Box I – Key Points
N 24 Cholera diagnostics tests have been developed since
1990, 14 of which have been reviewed in 18 peer-
reviewed analytical papers.
N The majority of the tests were RDTs and PCR technol-
ogies, others include agglutination and direct fluores-
cence antibodies.
N Overall the quality of peer-reviewed evaluations of
diagnostic tests for cholera is problematic with issues
raised in regards to sample size, sample types, gold
standard, context suitability for the testing of rapid
diagnostic tests and insufficient information provision
for test descriptors.
N DEEP guidelines propose a roadmap for standardised
evaluation studies of diagnostic technologies and ought
to be used to further evaluate the five RDTs that have
shown promise under field conditions; COAT, IP cholera
dipstick, SMART, IP dipstick and Medicos.
N The limited research and funding in this field highlight
the neglect of cholera and calls for increased coordina-
tion and prioritisation in the domain of R&D for cholera
diagnostic tests to promote early epidemic prevention.
Box II –Key papers
N Banoo S, Bell D, Bossuyt P, Herring A, Mabey D and Poole
F et al (2010). Evaluation of diagnostic tests for infectious
diseases: general principles. Nature Reviews Microbiolo-
gy; 8(12): S17–S29.
N Bhuiyan NA, Qadri F, Faruque AS, Malek MA, Salam MA,
et al. (2003). Use of dipsticks for rapid diagnosis of
cholera caused by Vibrio cholerae O1 and O139 from
rectal swabs. Journal of Clinical Microbiology; 41: 3939–
3941.
N Harris JR, Cavallaro EC, de Nobrega AA, Dos S Barrado JC,
Bopp C, et al. (2009). Field evaluation of Crystal VC Rapid
Dipstick test for cholera during a cholera outbreak in
Guinea-Bissau. Tropical Medicine & International Health;
14(9): 1117–21.
N Kalluri P, Naheed A, Rahman S, Ansaruzzaman M,
Faruque AS, et al. (2006). Evaluation of three rapid
diagnostic tests for cholera: does the skill level of the
technician matter? Tropical Medicine & International
Health; 11: 49–55.
N Nato F, Boutonnier A, Rajerison M, Grosjean P, Dartevelle
S, et al. (2003). One-step immunochromatographic
dipstick tests for rapid detection of Vibrio cholerae O1
and O139 in stool samples. Clinical and Diagnostic
Laboratory Immunology; 10: 476–478.
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selected to review only articles written in English from the year
1990 onwards. In spite of the aforementioned limitations of these
studies (see table 5), the authors present here a first attempt to
rank the existing tests according to sensitivity and specificity or
PPV and NPV (see tables 1–4). In doing so we have identified
that only five tests; COAT, IP cholera dipstick, SMART, IP
dipstick and Medicos have been evaluated under field conditions,
with a large enough sample size, providing data for essential
evaluation parameters. In light of these products’ low specificity
and sensitivity findings (some less than 90%) and non-indepen-
dent reporting of the data the authors strongly recommend
further studies assessing field performance of these promising
tests. International collaboration is called for to co-ordinate well
designed evaluation studies with standardized protocols, using
best gold standard and assess the test performance for the
intended use they were built for. From robust data sets, the
scientific community can then derive performance benchmarks
for each intended use of the available commercial cholera
diagnostic tests.
Caveats in the available information make it harder to make
overarching comparisons between the different diagnostic tools,
and so does the redundancy in product re-packaging under
different names. The neglected nature of cholera in terms of the
ratio of its burden to the relative attention it gets (funding,
awareness, research) means that most of the diagnostic tools
developed thus far have never progressed to mass production and
can only be found in small batch numbers for a short period of
time. This makes any future evaluation of these tools fraught with
difficulties. Much of the information about the respective
diagnostic tools has been provided by manufacturers in media
releases and product information and is therefore often lacking in
reliable information regarding the testing protocol. These are
aspects that a future evaluation could address by carrying out
independent testing of the products, facilitating an evidence-based
revision of the diagnostic strategies for cholera. The authors
recommend a prioritization of research and development agenda,
and would like to see the five promising field evaluated products
highlighted in this article (table 1 and 2) undergoing further
independent evaluation, followed by technical improvements if
needed and production for use in field condition. Ascertaining the
best RDT for early detection of epidemics in this way will
maximize the benefits using constrained financial resources
available.
Despite the limitations of this review, it is the first time a
comprehensive picture of the market of diagnostic tests for cholera
has been revealed. In doing so, many of the criteria for more
thorough investigation have been elucidated and will likely be
incorporated into future standard formulations of evaluation
guidelines. The authors hope that the availability and use of the
resulting reliable and user friendly rapid diagnostic tests will allow
for the triggering of timely response to outbreaks and thus limit
spread and burden of cholera.
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